UK drugmaker AstraZeneca on Saturday agreed to buy US biotechnology group Alexion Pharmaceuticals in a $39 billion cash-and-stock deal. This marks the biggest deal by a pharmaceutical company since the start of the coronavirus pandemic. Upon completion of the deal, Alexion shareholders will own about 15% of the combined company.